Figure 3.

(A) Least squares mean (LSM) changes from baseline in Short Form-36 Health Survey version 2 Physical Component Summary (SF-36v2 PCS) score and (B) spydergram of domain scores from baseline to month 3 versus age-matched and gender-matched norms. (A) *p≤0.05, **p<0.01, compared with placebo; results up to month 3 were based on a repeated measures model including data (norm-based) up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and combined placebo group. Results after month 3 were based on a second repeated-measures model including data up to end of study for the four treatment sequences (tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo → tofacitinib 5 mg twice daily and placebo → tofacitinib 10 mg twice daily), reporting results after month 3 only. Missing values were not imputed. Dashed line indicates end of placebo-controlled period. N represents the number of patients evaluable at each visit. (B) *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; spydergrams generated using domain raw scores (range: 0–100); US age-gender norms were matched to the protocol population; spydergrams are for illustrative purposes only; p values were generated using a repeated-measures model for comparisons with placebo based on LSM changes from baseline in domain norm-based scores at month 3 (table 1). Missing values were not imputed. BID, twice daily; BP, bodily pain; GH, general health; MH, mental health; PF physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.